Publication:
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters

Simple item page
dc.contributor.authorCorona, Diana
dc.contributor.authorPérez-Valero, Ignacio
dc.contributor.authorCamacho, Angela
dc.contributor.authorGutiérrez Liarte, Ángela
dc.contributor.authorMontero-Alonso, Marta
dc.contributor.authorAlemán, María Remedios
dc.contributor.authorRuiz-Seco, Pilar
dc.contributor.authorPérez González, Alexandre
dc.contributor.authorRiera, Melchor
dc.contributor.authorJarrin-Vera, Inmaculada
dc.contributor.authorRivero-Juárez, Antonio
dc.contributor.authorRivero, Antonio
dc.contributor.funderGilead Sciences (Spain)es_ES
dc.contributor.funderMinisterio de Sanidad (España)es_ES
dc.contributor.funderPlan Nacional de I+D+i (España)es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderUnión Europea. Comisión Europea. NextGenerationEUes_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)es_ES
dc.date.accessioned2024-03-18T15:26:24Z
dc.date.available2024-03-18T15:26:24Z
dc.date.issued2024-01
dc.description.abstractObjectives: The efficacy of BIC/FTC/TAF in HIV late presenters initiating antiretroviral therapy (ART) has not been sufficiently evaluated. Methods: The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts <200 cells/mm3 and/or AIDS-defining conditions between January 1st 2019 and November 30th 2020. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS) (primary objective), defined as HIV RNA <50 cop/mL, and immunological recovery (IR) (secondary objective), defined as CD4 count >200 cells/mm3, at weeks 24 and 48 after initiation of ART. Results: We evaluated 314 individuals (84.7% men, median age 40 years). Of them, 158 initiated with BIC/FTC/TAF. At inclusion, 117 had an AIDS-defining condition. In multivariable analyses, individuals with AIDS-defining conditions initiating ART with BIC/FTC/TAF achieved higher rates of VS at 24 weeks than other regimens (aOR: 0.2; 95% CI: 0.06-0.64) and, at 48 weeks, than DTG/ABC/3TC (aOR: 0.06; 95% CI: 0.01-0.76) and DTG + TDF/3TC (aOR: 0.2; 95% CI: 0.47-0.9). No other differences in VS or IR were observed. At 24 and 48 weeks after ART initiation, treatment discontinuations were lower with BIC/FTC/TAF than with other regimens (3.2% and 7.6% vs. 24.4% and 37.8%, respectively; P < 0.005). Conclusion: Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters because of its high effectiveness and good tolerability.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThe CORIS Cohort and Gilead Sciences. This work was supported by the Ministerio de Sanidad (RD12/0017/0012) integrated in the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). Projects PI22/01098 and PI21/00793, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-Next Generation EU.es_ES
dc.format.number1es_ES
dc.format.page107016es_ES
dc.format.volume63es_ES
dc.identifier.citationInt J Antimicrob Agents. 2024 Jan;63(1):107016.es_ES
dc.identifier.doi10.1016/j.ijantimicag.2023.107016es_ES
dc.identifier.e-issn1872-7913es_ES
dc.identifier.journalInternational journal of antimicrobial agentses_ES
dc.identifier.pubmedID37890734es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18995
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0012/ES/SIDA/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI22%2F01098/ES/Magnitud e impacto clínico de la infección por Orthohepevirus C/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI21%2F00793/ES/EVALUACION DE LA INFECCION POR ORTHOHEPEVIRUS C COMO CAUSA EMERGENTE DE ENFERMEDAD DE ORIGEN ZOONÓTICO/es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.ijantimicag.2023.107016es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAdvance HIV diseasees_ES
dc.subjectBIC/FTC/TAFes_ES
dc.subjectART initiationes_ES
dc.subjectNaïvees_ES
dc.subject.meshAnti-HIV Agentses_ES
dc.subject.meshAcquired Immunodeficiency Syndromees_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshPiperazineses_ES
dc.subject.meshPyridoneses_ES
dc.subject.meshAlaninees_ES
dc.subject.meshAmideses_ES
dc.subject.meshHeterocyclic Compounds, 3-Ringes_ES
dc.subject.meshAdultes_ES
dc.subject.meshMalees_ES
dc.subject.meshHumanses_ES
dc.subject.meshFemalees_ES
dc.subject.meshDrug Combinationses_ES
dc.subject.meshEmtricitabinees_ES
dc.subject.meshTenofovires_ES
dc.titleEffectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenterses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
Files
Collections
Centro Nacional de Epidemiología (CNE)
IISGS - Instituto de Investigación Sanitaria Galicia Sur (Galicia)
IMIBIC - Instituto Maimónides de Investigación Biomédica de Córdoba (Andalucía)